Sigilon Therapeutics, Inc. SGTX
Set alert
At close · Aug 10
52-week range unavailable
- Open
- 22.90
- Prev close
- 22.47
- Mkt cap
- 53.57M
- Vol
- 81.88K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 22.09
- High
- 23.08
- Forward P/E
- -1.66
- Beta
- 4.17
- Short ratio
- 0.76
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 7, 2023
- 50-d avg
- 8.55
- 200-d avg
- 8.23
- 1y target
- 47.33
Key statistics
- Market cap
- 53.57M
- Enterprise value
- 23.24M
- Trailing P/E
- 0.00
- Forward P/E
- -1.66
- PEG ratio
- 0.00
- Price / sales
- 3.66
- Price / book
- 1.61
- EPS (TTM)
- -14.82
- Beta
- 4.17
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -253.33%
- Revenue (TTM)
- 14.64M
- Revenue growth
- 53.50%
- Free cash flow
- -31.71M
- Total cash
- 56.37M
- Total debt
- 25.47M
- Return on equity
- -75.77%
- Shares outstanding
- 2.50M
- Short % of float
- 0.56%
- 50-day average
- 8.55
- 200-day average
- 8.23
Analyst view
Consensus: buy
- Target (low)
- 21.00
- Target (mean)
- 47.33
- Target (high)
- 91.00
Next earnings
Aug 7, 2023
Expected Aug 7, 2023. Consensus EPS estimate -4.71.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 7, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
| May 9, 2023 | Mar 1, 2023 | 0.00 | — | — | — |
| Mar 14, 2023 | Dec 1, 2022 | 0.00 | — | — | — |
| Nov 10, 2022 | Sep 1, 2022 | -5.59 | — | — | — |
| Aug 4, 2022 | Jun 1, 2022 | -5.98 | — | — | — |
| May 12, 2022 | Mar 1, 2022 | -3.90 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 18, 2023 | Canaccord Genuity | init | — | Buy |
| Dec 23, 2021 | Canaccord Genuity | main | — | Buy |
| Dec 1, 2021 | Barclays | main | — | Overweight |
| Nov 30, 2021 | Morgan Stanley | main | — | Equal-Weight |
| Nov 30, 2021 | Jefferies | down | Buy | Hold |
| Oct 29, 2021 | BTIG | init | — | Buy |
About Sigilon Therapeutics, Inc.
Sigilon Therapeutics, Inc., a preclinical stage biotechnology company, develops functional cures for patients with acute and chronic diseases. Its lead product candidate is SIG-002 to replace islet cells for the treatment of type 1 diabetes; and SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-205, SIG-218, SIG-220, and SIG-005, which are to treat the non-neurological manifestations of mucopolysaccharidosis type 1; and SIG-207 is to treat of Fabry disease. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- sigilon.com
News
- Lilly Completes Acquisition of Sigilon Therapeutics
- SIGILON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sigilon Therapeutics, Inc. - SGTX
- Benzinga's Top Ratings Upgrades, Downgrades For June 30, 2023
- Sigilon (SGTX) Skyrockets 441% on Buyout Offer From Eli Lilly
- Eli Lilly to buy Sigilon Therapeutics on a massive premium
- Eli Lilly to Acquire Sigilon Therapeutics
- Eli Lilly to buy Sigilon Therapeutics to expand diabetes treatments
- Why Is Sigilon Therapeutics (SGTX) Stock Up 691% Today?
- Lilly to Acquire Sigilon Therapeutics
- Sigilon Therapeutics to Present at the Needham Virtual Healthcare Conference
Your note
Sign in to keep a note on SGTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANDERSON DANIEL GRIFFITH | Director | Sale | Jun 1, 2021 | 2,022,220 |
| COX JOHN | Director | Conversion of Exercise of derivative security | Dec 7, 2020 | 0 |
| ELI LILLY & CO | Beneficial Owner of more than 10% of a Class of Security | Purchase | Dec 7, 2020 | 2,744,440 |
| FLAGSHIP VENTURES FUND V GENERAL PARTNER L.L.C | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Dec 7, 2020 | 0 |
| PONTES JOSIAS | Officer | Stock Award(Grant) | Sep 29, 2021 | 13,339 |
| RUFFOLO ROBERT R JR | Director | Sale | Jun 30, 2021 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Flagship Pioneering Inc. | 2.45% | 797,720 | 17.08M | Mar 30, 2023 |
| Canada Pension Plan Investment Board | 0.35% | 114,245 | 2.45M | Mar 30, 2023 |
| FMR, LLC | 0.25% | 81,123 | 1.74M | Mar 30, 2023 |
| Blackrock Inc. | 0.25% | 80,706 | 1.73M | Mar 30, 2023 |
| Cercano Management LLC | 0.21% | 68,071 | 1.46M | Mar 30, 2023 |
| Harbourvest Partners, LLC | 0.18% | 56,980 | 1.22M | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BlackRock Health Sciences Trust II | 1.74% | 564,538 | 12.09M | Dec 30, 2022 |
| Fidelity Growth Company Fund | 1.15% | 374,436 | 8.02M | Feb 27, 2023 |
| Blackrock Funds-Health Sciences Opportunity Portfolio | 1.02% | 332,626 | 7.12M | Feb 27, 2023 |
| Vanguard Total Stock Market Index Fund | 0.56% | 181,760 | 3.89M | Dec 30, 2022 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.39% | 125,000 | 2.68M | Dec 30, 2022 |
| Fidelity Growth Company K6 Fund | 0.33% | 107,734 | 2.31M | Feb 27, 2023 |